Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.

Le X, Eisert A, Hsia TC, Raut NV, Ahmad A, Chan OSH, De Bondt C, Farrugia D, Froesch P, González-Cao M, Hendriks L, Hochmair MJ, Mazieres J, O'Sullivan H, Popat S, Samol J, van der Wekken AJ, Yang TY, Tho LM, Himpe U, Lam WS, Lee KWC, Petrini I, Berghoff K, Karachaliou N, Joshi K, Vlassak S, Chang GC

Open source

DOI: 10.1016/j.cllc.2025.02.013
Published: 2025 Jun
Container: Clinical lung cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2025.02.013,
  title = {Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.},
  author = {Le X and Eisert A and Hsia TC and Raut NV and Ahmad A and Chan OSH and De Bondt C and Farrugia D and Froesch P and González-Cao M and Hendriks L and Hochmair MJ and Mazieres J and O'Sullivan H and Popat S and Samol J and van der Wekken AJ and Yang TY and Tho LM and Himpe U and Lam WS and Lee KWC and Petrini I and Berghoff K and Karachaliou N and Joshi K and Vlassak S and Chang GC},
  year = {2025},
  journal = {Clinical lung cancer},
  doi = {10.1016/j.cllc.2025.02.013},
  url = {https://doi.org/10.1016/j.cllc.2025.02.013}
}

RIS

TY  - JOUR
TI  - Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.
AU  - Le X
AU  - Eisert A
AU  - Hsia TC
AU  - Raut NV
AU  - Ahmad A
AU  - Chan OSH
AU  - De Bondt C
AU  - Farrugia D
AU  - Froesch P
AU  - González-Cao M
AU  - Hendriks L
AU  - Hochmair MJ
AU  - Mazieres J
AU  - O'Sullivan H
AU  - Popat S
AU  - Samol J
AU  - van der Wekken AJ
AU  - Yang TY
AU  - Tho LM
AU  - Himpe U
AU  - Lam WS
AU  - Lee KWC
AU  - Petrini I
AU  - Berghoff K
AU  - Karachaliou N
AU  - Joshi K
AU  - Vlassak S
AU  - Chang GC
PY  - 2025
JO  - Clinical lung cancer
DO  - 10.1016/j.cllc.2025.02.013
UR  - https://doi.org/10.1016/j.cllc.2025.02.013
ER  -

APA

X, L., A, E., TC, H., NV, R., A, A., OSH, C., C, D. B., D, F., P, F., M, G., L, H., MJ, H., J, M., H, O., S, P., J, S., AJ, V. D. W., TY, Y., LM, T., U, H., WS, L., KWC, L., I, P., K, B., N, K., K, J., S, V., & GC, C. (2025). Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2025.02.013

Source records

pubmed · retrieved 2026-09-26T13:25:44.885Z
europe-pmc · retrieved 2026-09-26T13:25:44.884Z